SAB Biotherapeutics, Inc. (SABS) Key Metrics
SABS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $230.2M
- Enterprise value
- $211.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.0
- Price / book
- 1.5
- EV / EBITDA
- 64.2
- Dividend yield
- —
- Beta
- 0.58
SABS key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSABS returns How much profit the business earns on the capital it uses.
SABS financial health Debt, liquidity and how easily interest is covered.
SABS efficiency & capital use Working capital cycle and where the cash goes.
SABS valuation history
SABS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SABS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SABS cash returned to shareholders
SABS price vs earnings per share
SABS key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $229.4M | — | — | — | — | — | — |
| Enterprise value | $138.8M | — | — | — | — | — | — |
| P/E ratio | 17.3 | — | — | — | — | — | — |
| Price / book | 1.5 | — | — | — | — | — | — |
| EV / EBITDA | 8.4 | — | — | — | — | — | — |
| Earnings yield | 5.8% | — | — | — | — | — | — |
| Free cash flow yield | −19.9% | — | — | — | — | — | — |
| Share price at fiscal year-end | $3.74 | $3.79 | $6.88 | $5.90 | $78.10 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | — | — | — | — | — | — |
| Earnings per share | $0.22 | — | — | — | — | — | — |
| Operating cash flow per share | −$0.73 | — | — | — | — | — | — |
| Free cash flow per share | −$0.75 | — | — | — | — | — | — |
| Cash per share | $1.57 | — | — | — | — | — | — |
| Book value per share | $2.47 | — | — | — | — | — | — |
| Tangible book value per share | $2.47 | — | — | — | — | — | — |
| Capex per share | $0.02 | — | — | — | — | — | — |
| Debt per share | $0.10 | — | — | — | — | — | — |
| Shares outstanding | 61.3M | — | — | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | 15.0% | −81.9% | −95.5% | −53.8% | −44.2% | 109.6% | — |
| Return on invested capital (ROIC) | −109.4% | −410.4% | −210.5% | −127.6% | −43.7% | 119.8% | — |
| Return on assets (ROA) | 12.2% | −53.2% | −62.6% | −28.4% | −24.9% | 54.0% | −49.9% |
| Return on tangible assets | 7.7% | −77.2% | −50.3% | −36.8% | −21.1% | 35.6% | −49.9% |
| Free cash flow margin | — | — | — | −107.2% | −14.7% | −4.9% | −285.4% |
| Income quality (OCF / net income) | −3.37 | — | — | — | — | 0.50 | — |
| Financial health | |||||||
| Total debt | $6.0M | $4.7M | $5.9M | $5.9M | $8.5M | $8.1M | $7.6M |
| Cash & short-term investments | $96.6M | $20.8M | $56.6M | $15.0M | $33.2M | $12.6M | $6.3M |
| Net debt | −$90.6M | −$16.1M | −$50.7M | −$9.1M | −$24.7M | −$4.5M | $1.3M |
| Debt / equity | 0.04 | 0.18 | 0.10 | 0.19 | 0.22 | 0.21 | — |
| Debt / assets | 0.03 | 0.11 | 0.07 | 0.12 | 0.10 | 0.14 | 0.42 |
| Net debt / EBITDA | −5.46 | — | — | — | — | −0.21 | — |
| Current ratio | 9.46 | 2.98 | 5.45 | 1.47 | 1.90 | 3.11 | 2.01 |
| Quick ratio | 9.46 | 2.98 | 5.45 | 1.47 | 1.90 | 3.11 | 2.01 |
| Interest coverage | -203.4 | -134.8 | -120.8 | -95.9 | -45.5 | 43.8 | -20.2 |
| Working capital | $90.4M | $15.8M | $48.1M | $7.1M | $23.7M | $23.4M | $4.7M |
| Invested capital | $60.9M | $9.9M | $6.6M | $21.9M | $13.9M | $34.5M | −$1.0M |
| Tangible asset value | $151.5M | $26.0M | $57.3M | $31.1M | $38.5M | $39.0M | −$2.3M |
| Net current asset value | $79.7M | $5.6M | $32.3M | $2.3M | $7.6M | $16.9M | −$11.0M |
| Graham number | $3.47 | — | — | — | — | — | — |
| Graham net-net per share | $1.24 | — | — | — | — | — | — |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | $0 | $5.5M | $0 | — | — |
| Capex / revenue | — | 25.5% | 8.8% | 9.1% | 18.0% | 23.0% | 17.7% |
| Capex / operating cash flow | — | — | — | — | 550.8% | 127.3% | — |
| Capex / depreciation | 0.30 | 0.07 | 0.05 | 0.66 | 6.62 | 23.23 | 1.88 |
| Stock-based compensation / revenue | — | 222.5% | 108.3% | 11.2% | 3.8% | 2.3% | 10.8% |
| R&D / revenue | — | 2,281.1% | 737.6% | 152.4% | 93.9% | 50.5% | 233.0% |
| SG&A / revenue | — | 1,057.2% | 1,062.9% | 68.5% | 28.1% | 12.3% | 119.0% |
| Efficiency | |||||||
| Days sales outstanding | — | 7.6 | 452.9 | 103.6 | 85.7 | 77.3 | 298.9 |
| Days payables outstanding | 286.7 | 100.6 | 225.4 | 451.1 | 1,306.5 | — | — |
| Cash conversion cycle (days) | — | -93.0 | 227.5 | -347.5 | -1,220.8 | — | — |
| Receivables turnover | 0.00 | 48.13 | 0.81 | 3.52 | 4.26 | 4.72 | 1.22 |
| Payables turnover | 1.27 | 3.63 | 1.62 | 0.81 | 0.28 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.02 | 0.03 | 0.36 | 0.88 | 1.48 | 0.19 |
| Average receivables | $500,868 | $27,478 | $2.8M | $6.8M | $14.3M | $11.7M | $2.8M |
| Average payables | $2.4M | $1.3M | $2.3M | $4.1M | $5.9M | $4.8M | $2.2M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SABS's annual financial statements (latest annual report filed March 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SABS valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), SAB Biotherapeutics traded at 17.3 times earnings. SAB Biotherapeutics earned a return on equity of 15.0% and a return on invested capital of −109.4% in fiscal 2025. It ended the year with $6.0 million of debt and $96.6 million in cash and short-term investments, a net cash position of $90.6 million.
See the SABS income statement, the SABS chart for price history, or the SABS stock overview for the latest quote and news.
SABS key metrics FAQ
What is SAB Biotherapeutics's P/E ratio?
SAB Biotherapeutics traded at 17.3 times earnings at the end of fiscal 2025.
What is SAB Biotherapeutics's EV/EBITDA?
SAB Biotherapeutics's enterprise value was 8.4 times EBITDA at the end of fiscal 2025 (enterprise value $138.8 million, EBITDA $16.6 million); the current EV/EBITDA is 64.2.
What is SAB Biotherapeutics's return on equity?
SAB Biotherapeutics's return on equity (ROE) was 15.0% in fiscal 2025: net income of $13.3 million on average shareholders' equity of $88.7 million.
What is SAB Biotherapeutics's ROIC?
SAB Biotherapeutics's return on invested capital was −109.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does SAB Biotherapeutics have?
SAB Biotherapeutics had total debt of $6.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.04 and more cash than debt.
What is SAB Biotherapeutics's free cash flow yield?
SAB Biotherapeutics generated -$45.7 million of free cash flow in fiscal 2025, a free cash flow yield of −19.9% on its market value at year-end ($229.4 million).
What is SAB Biotherapeutics's current ratio?
SAB Biotherapeutics's current ratio was 9.46 at the end of fiscal 2025: current assets were 9.46 times current liabilities.